Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116883 · ClinicalTrials.gov registry record · Phase 3
A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT00116883 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 90 participants.
The verdict
NCT00116883, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of an aqueous nasal spray investigational compound GW685698X compared to placebo on the hypothalamic pituitary adrenocortical (HPA) axis system in children 2 to 11 years of age with perennial allergic rhinitis.
Interventions
- DRUG GW685698X aqueous nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2005-02 |
| Est. Completion | 2005-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116883
The ClinicalTrials.gov registry entry for NCT00116883 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GW685698X aqueous nasal spray is the first listed.
NCT00116883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116883 about?
NCT00116883 is a clinical study titled "A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics". The purpose of this study is to assess the effect of an aqueous nasal spray investigational compound GW685698X compared to placebo on the hypothalamic pituitary adrenocortical (HPA) axis system in children 2 to 11 years of age with perennial allergic rhinitis.
What is the current status of trial NCT00116883?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2005-02. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00116883?
The interventions under investigation include: GW685698X aqueous nasal spray (DRUG).
Who is sponsoring clinical trial NCT00116883?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.